Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Down 86.7% in December

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 10,300 shares, a decrease of 86.7% from the December 15th total of 77,600 shares. Based on an average trading volume of 153,100 shares, the short-interest ratio is currently 0.1 days.

Bioxytran Stock Down 3.5 %

Shares of BIXT opened at $0.10 on Tuesday. The stock has a market cap of $8.24 million, a PE ratio of -9.50 and a beta of -0.55. Bioxytran has a 52-week low of $0.06 and a 52-week high of $0.15. The firm’s fifty day moving average is $0.09 and its two-hundred day moving average is $0.10.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.